LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

12.04 1.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.52

Max

12.19

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

108.767

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+60.88% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.21%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-138M

230M

Iepriekšējā atvēršanas cena

10.09

Iepriekšējā slēgšanas cena

12.04

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. febr. 22:04 UTC

Peļņas

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

2026. g. 26. febr. 23:55 UTC

Tirgus saruna

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

2026. g. 26. febr. 23:40 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

2026. g. 26. febr. 23:37 UTC

Tirgus saruna

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

2026. g. 26. febr. 23:32 UTC

Peļņas

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

2026. g. 26. febr. 23:19 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

2026. g. 26. febr. 23:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

2026. g. 26. febr. 23:12 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2026. g. 26. febr. 23:12 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Gives Up in Bidding War Over Warner -- Market Talk

2026. g. 26. febr. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026. g. 26. febr. 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026. g. 26. febr. 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

2026. g. 26. febr. 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026. g. 26. febr. 22:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 26. febr. 22:43 UTC

Tirgus saruna

RBA Hike In March Is Being Underpriced -- Market Talk

2026. g. 26. febr. 22:33 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

2026. g. 26. febr. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

2026. g. 26. febr. 22:13 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Bidding War Over Warner Bros. Set to Continue -- Market Talk

2026. g. 26. febr. 21:59 UTC

Peļņas

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

2026. g. 26. febr. 21:58 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

2026. g. 26. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 26. febr. 21:49 UTC

Peļņas

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

2026. g. 26. febr. 21:45 UTC

Peļņas

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

2026. g. 26. febr. 21:44 UTC

Peļņas

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

2026. g. 26. febr. 21:44 UTC

Peļņas

Coles Expects Market to Remain Highly Competitive

2026. g. 26. febr. 21:44 UTC

Peļņas

Coles Says Supermarket Customers Remain Value Oriented

2026. g. 26. febr. 21:43 UTC

Peļņas

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

2026. g. 26. febr. 21:43 UTC

Peļņas

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

2026. g. 26. febr. 21:42 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

2026. g. 26. febr. 21:41 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

60.88% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  60.88%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat